The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | The importance of CD47 as a target in MDS and AML
In this video, Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the importance of CD47 as a target in various hematological malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and lymphoma. Dr Daver also comments on current trials investigating the impact of CD47 inhibition. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
